Standard Biotools Inc Overview
Industry: Diagnostics & Research
Sector: Healthcare
Standard BioTools Inc., together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Standard BioTools Inc., together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion Read MoreReported Results
What the company reported, with filing details kept small.
Quarterly result summary
Stored reported-result values did not pass automated reconciliation.
What changed
- Open the SEC source filing while these values are reprocessed.
Source review
Mavefund has withheld unreconciled figures from the public page.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
Aug 05, 2026
SEC filing
8-K
Aug 05, 2026
SEC filing
10-Q
May 06, 2026
SEC filing
8-K
May 05, 2026
Earnings release
Earnings release
May 05, 2026
SEC filing
10-K
Mar 16, 2026
SEC filing
8-K
Feb 24, 2026
Earnings release
Earnings release
Feb 24, 2026
SEC filing
EXHIBIT 99.1
Jan 30, 2026
SEC filing
8-K
Jan 08, 2026
Earnings release
Earnings release
Jan 08, 2026
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Rocket Lab misses EPS estimate despite record revenue
Headline from Yahoo Finance: Rocket Lab misses EPS estimate despite record revenue.
Rocket Lab Announces Second Quarter 2026 Financial Results: Posts Record Revenue and Record Backlog, Guides To Another Record Revenue Quarter in Q3 2026
Headline from Yahoo Finance: Rocket Lab Announces Second Quarter 2026 Financial Results: Posts Record Revenue and Record Backlog, Guides To Another Record Revenue Quarter in Q3 2026.
Rocket Lab's CEO Wants His Company to Become a 'Self-Licking Ice Cream'— Here's What That Means
Headline from Yahoo Finance: Rocket Lab's CEO Wants His Company to Become a 'Self-Licking Ice Cream'— Here's What That Means.
Rocket Lab Stock Tumbles After Q2 Earnings Misses Estimate
Headline from Yahoo Finance: Rocket Lab Stock Tumbles After Q2 Earnings Misses Estimate.
Rocket Lab USA, Inc. Q2 2026 Earnings Call Summary
Headline from Yahoo Finance: Rocket Lab USA, Inc. Q2 2026 Earnings Call Summary.
Rocket Lab Q2 2026 earnings: revenue up 62%, loss widens
Headline from Yahoo Finance: Rocket Lab Q2 2026 earnings: revenue up 62%, loss widens.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.